title: Cytokine related therapies for autoimmune disease.
abstract: In short, manipulation of cytokine pathways shows promise as a mean to tilt the balance of immunity toward tolerance. Effective and regulatory T cells vary in their response to a variety of cytokines. In particular, the ability of certain cytokines, for example, IL-2, to provide vital survival signals to regulatory cells and to trigger death of effector T cells or impede IL-15 driven expansion of memory cells has spurred several trials. The ability of IFNgamma, IL-4, TNFalpha, and lymphotoxin to exert selective effects upon crucial lymphocyte subset populations in vivo may also enable translation into potent therapies.
authors.affiliation: Harvard Medical School, Beth Israel Deaconess Medical Center, Center for Life Sciences Building, 3 Blackfan Circle, Boston, MA 02115, United States. 0Htstrom@bidmc.harvard.edu
authors.forename: Terry B
authors.initials: TB
authors.lastname: Strom
authors.forename: Maria
authors.initials: M
authors.lastname: Koulmanda
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D016207:Cytokines